Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient
- PMID: 24222608
- PMCID: PMC3837859
- DOI: 10.1128/AAC.01112-13
Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient
Comment in
-
Reply to "Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient".Antimicrob Agents Chemother. 2013 Dec;57(12):6413-4. doi: 10.1128/AAC.01587-13. Antimicrob Agents Chemother. 2013. PMID: 24222609 Free PMC article. No abstract available.
Comment on
-
Risk factors for a low linezolid trough plasma concentration in acute infections.Antimicrob Agents Chemother. 2013 Apr;57(4):1913-7. doi: 10.1128/AAC.01694-12. Epub 2013 Feb 12. Antimicrob Agents Chemother. 2013. PMID: 23403416 Free PMC article.
Similar articles
-
Reply to "Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient".Antimicrob Agents Chemother. 2013 Dec;57(12):6413-4. doi: 10.1128/AAC.01587-13. Antimicrob Agents Chemother. 2013. PMID: 24222609 Free PMC article. No abstract available.
-
Usefulness of monitoring linezolid trough serum concentration in prolonged treatments.Rev Esp Quimioter. 2011 Sep;24(3):151-3. Rev Esp Quimioter. 2011. PMID: 21947098
-
Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis.Antimicrob Agents Chemother. 2007 May;51(5):1661-5. doi: 10.1128/AAC.00744-06. Epub 2007 Mar 12. Antimicrob Agents Chemother. 2007. PMID: 17353251 Free PMC article.
-
Enterococcus faecalis resistant to linezolid: case series and review of the literature.Pharmacotherapy. 2004 Sep;24(9):1225-31. doi: 10.1592/phco.24.13.1225.38086. Pharmacotherapy. 2004. PMID: 15460184 Review.
-
Use of linezolid in children: an overview of recent advances.Expert Rev Anti Infect Ther. 2006 Dec;4(6):947-52. doi: 10.1586/14787210.4.6.947. Expert Rev Anti Infect Ther. 2006. PMID: 17181410 Review.
Cited by
-
Reply to "Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient".Antimicrob Agents Chemother. 2013 Dec;57(12):6413-4. doi: 10.1128/AAC.01587-13. Antimicrob Agents Chemother. 2013. PMID: 24222609 Free PMC article. No abstract available.
-
What's New in the Treatment of Enterococcal Endocarditis?Curr Infect Dis Rep. 2014 Oct;16(10):431. doi: 10.1007/s11908-014-0431-z. Curr Infect Dis Rep. 2014. PMID: 25165018 Free PMC article.
-
Prevalence of vancomycin-variable Enterococcus faecium (VVE) among vanA-positive sterile site isolates and patient factors associated with VVE bacteremia.PLoS One. 2018 Mar 22;13(3):e0193926. doi: 10.1371/journal.pone.0193926. eCollection 2018. PLoS One. 2018. PMID: 29566004 Free PMC article.
References
-
- Livermore DM. 2003. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51(Suppl 2):ii9–ii16 - PubMed
-
- Clinical and Laboratory Standards Institute 2013. Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA
-
- Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. 2003. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin. Pharmacokinet. 42:1411–1423 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical